Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders
A new approach is adopted to treat primary immunodeficiency disorders, such as the severe combined immunodeficiency (SCID; e.g., adenosine deaminase SCID [ADA-SCID] and IL-2 receptor X-linked severe combined immunodeficiency [SCID-X1]). The success, along with the feasibility of gene therapy, is und...
Guardado en:
Autores principales: | Odiba Arome Solomon, Okoro Nkwachukwu Oziamara, Durojaye Olanrewaju Ayodeji, Wu Yanjun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/375714475dc643baa2b39f505edeb293 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Haowei (Linda) Sun, et al.
Publicado: (2021) -
Skull hemophilia pseudotumor: A case report
por: Lin Kunzhe, et al.
Publicado: (2021) -
Promoting Sports Practice in Persons with Hemophilia: A Survey of Clinicians’ Perspective
por: Giuseppe Lassandro, et al.
Publicado: (2021) -
Sports and Children with Hemophilia: Current Trends
por: Lorenzo Moretti, et al.
Publicado: (2021) -
Hemoglobin
Publicado: (1976)